SalioGen Therapeutics, led by Ray Tabibiazar, shut down after failing to perfect its bat-derived gene editing technology.

Aviva Capital Partners & Socius plan £1B cancer research hub in Sutton, UK, near Institute of Cancer Research & Royal Marsden ...

FDA delays Cytokinetics' aficamten PDUFA date to Dec 26 after company adds REMS to heart disease drug application; stock down ...

While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play ...

HHS Secretary Robert F. Kennedy Jr. claimed that moving forward, all new vaccines will need to be tested in ...

Bristol Myers Squibb closing viral vector site in Libertyville, IL, shifting production to Devens, MA; affects workers from ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

Icon and Medpace report high R&D project cancellations; Icon sees $659M in Q1 cancellations, cuts guidance; Medpace notes ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Moderna is expanding a cost control program as it seeks to break even in the coming years, despite challenges for vaccine ...

Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...